We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

CCH Treatment of Cellulite in the Presence of Dermal Laxity With Comparison Between Two (2) Different Injection Techniques

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04580303
Recruitment Status : Completed
First Posted : October 8, 2020
Results First Posted : September 28, 2022
Last Update Posted : September 28, 2022
Sponsor:
Information provided by (Responsible Party):
Endo Pharmaceuticals

Brief Summary:
This study is designed to investigate the safety and efficacy of collagenase clostridium histolyticum (CCH) for the treatment of mild to moderate edematous fibrosclerotic panniculopathy (cellulite) in participants with moderate to severe dermal laxity in the buttocks or thighs with comparison between two (2) different CCH injection techniques.

Condition or disease Intervention/treatment Phase
Edematous Fibrosclerotic Panniculopathy Cellulite Laxity; Skin Drug: collagenase clostridium histolyticum Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 35 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Multicenter, Open-label, Randomized, Parallel-group, Multiple-dose Study to Assess the Effectiveness, Safety and Satisfaction With Collagenase Clostridium Histolyticum Grid Technique Injections of Buttock or Thigh Cellulite With Laxity in Adult Females
Actual Study Start Date : October 1, 2020
Actual Primary Completion Date : August 30, 2021
Actual Study Completion Date : September 24, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Uniform 0.1-milliliters (mL) 1-Aliquot Grid Injection Technique (Buttock)
Dose per participant per treatment visit = up to 1.68 milligrams (mg) of CCH (0.84 mg in each treatment area)
Drug: collagenase clostridium histolyticum
Delivered via uniform grid injection techniques.
Other Names:
  • EN3835
  • CCH

Active Comparator: Uniform 0.3-mL 2-Aliquot Grid Injection Technique (Buttock)
Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)
Drug: collagenase clostridium histolyticum
Delivered via uniform grid injection techniques.
Other Names:
  • EN3835
  • CCH

Active Comparator: Uniform 0.1-mL 1-Aliquot Grid Injection Technique (Thigh)
Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)
Drug: collagenase clostridium histolyticum
Delivered via uniform grid injection techniques.
Other Names:
  • EN3835
  • CCH

Active Comparator: Uniform 0.3-mL 2-Aliquot Grid Injection Technique (Thigh)
Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)
Drug: collagenase clostridium histolyticum
Delivered via uniform grid injection techniques.
Other Names:
  • EN3835
  • CCH




Primary Outcome Measures :
  1. Percentage of 1-Level Responders (+1 or Better Score) on the Investigator-Global Aesthetic Improvement Scale (I-GAIS) for Either Buttock or Either Thigh [ Time Frame: Day 180 ]
    I-GAIS is a 7-point scale rating global aesthetic improvement in appearance, compared to pretreatment, as judged by the investigator ranging from "Very Much Worse" (-3), "Much Worse" (-2), "Worse" (-1), "No Change" (0), "Improved" (+1), "Much Improved" (+2), and "Very Much Improved" (+3). One-level I-GAIS Responder for a treatment area (left buttock, right buttock, left thigh, or right thigh) was defined as any participant with an improved (+1, +2 or +3) score on the I-GAIS at the analysis visit for that treatment area. The percentage of participants who were 1-level responders for either buttock (right or left) or either thigh (right or left) is presented.


Secondary Outcome Measures :
  1. Percentage of 1-Level Responders (+1 or Better Score) on the I-GAIS for Either Buttock or Either Thigh [ Time Frame: Days 28, 56, 84, 112, and 140 ]
    I-GAIS is a 7-point scale rating global aesthetic improvement in appearance, compared to pretreatment, as judged by the investigator ranging from "Very Much Worse" (-3), "Much Worse" (-2), "Worse" (-1), "No Change" (0), "Improved" (+1), "Much Improved" (+2), and "Very Much Improved" (+3). One-level I-GAIS Responder for a treatment area (left buttock, right buttock, left thigh, or right thigh) was defined as any participant with an improved (+1, +2 or +3) score on the I-GAIS at the analysis visit for that treatment area. The percentage of participants who were 1-level responders for either buttock (right or left) or either thigh (right or left) is presented.

  2. Percentage of 1-Level Responders (+1 or Better Score) on the Subject Global Aesthetic Improvement Scale (S-GAIS) for Either Buttock or Either Thigh [ Time Frame: Days 28, 56, 84, 112, 140, and 180 ]
    S-GAIS assessments were based on digital photographs, and were performed separately for each of 2 treatment areas. S-GAIS is a 7-point scale rating global aesthetic improvement in appearance, compared to pretreatment, as judged by the participant ranging from "Very Much Worse" (-3), "Much Worse" (-2), "Worse" (-1), "No Change" (0), "Improved" (+1), "Much Improved" (+2), and "Very Much Improved" (+3). One-level S-GAIS Responder for a treatment area (left buttock, right buttock, left thigh, or right thigh) was defined as any participant with an improved (+1, +2 or +3) score on the S-GAIS at the analysis visit for that treatment area. The percentage of participants who were 1-level responders for either buttock (right or left) or either thigh (right or left) is presented.

  3. Change From Baseline in Body-Q Appraisal of Cellulite Total Score [ Time Frame: Baseline, Day 180 ]
    The Body-Q Appraisal of Cellulite is a subset of 11 questions from the Body-Q questionnaire developed to measure participant perceptions of weight loss and/or body contouring. Total score is the sum of all 11 question scores. The minimum possible total score is 11 and the maximum possible total score is 44. Higher scores indicate the individual is less bothered by their cellulite.

  4. Change From Baseline in Hexsel Cellulite Severity Scale (CSS) Subsection D Severity Score [ Time Frame: Baseline, Days 28, 56, 84, 112,140, and 180 ]
    Hexsel CSS is a photonumeric scale that looks at 5 key morphologic features of cellulite using a 4-point scale from a low of 0 to high of 3: 0 (absence of laxity, flaccidity, or sagging skin), 1 (slight draped appearance), 2 (moderate draped appearance), and 3 (severe draped appearance). The investigator or qualified designee used the Hexsel CSS Subsection D to assess the severity of dermal laxity in each buttock or each thigh independently. A decrease from baseline indicated a better outcome.

  5. Percentage of Participants Positive for Anti-AUX-I and Anti-AUX-II Antibodies [ Time Frame: Day 180 ]
    Blood samples were collected to assess anti-clostridial class I collagenase (AUX-I) and anti-Clostridial class II collagenase (AUX-II) antibody levels. The percentage of participants who were positive for anti-AUX-I and anti-AUX-II antibodies are presented.

  6. Percentage of Participants Positive for Neutralizing Antibodies to AUX-I and AUX-II [ Time Frame: Day 180 ]
    Blood samples were collected to assess neutralizing antibodies to AUX-I and AUX-II. The percentage of participants who were positive for neutralizing antibodies to AUX-I and AUX-II are presented.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Have a body mass index of 18 to <29.9 kilograms/square meters
  2. Have either both buttocks or both posterolateral thighs with:

    1. Score of 2 or 3 (mild or moderate cellulite) as reported by the investigator using the Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS)
    2. Hexsel Cellulite Severity Scale (CSS) Subsection D "Grade of Laxity, Flaccidity, or Sagging Skin" score of 2 or 3 (moderate or severe) as determined by the investigator
  3. Have a negative pregnancy test or be of non-childbearing potential
  4. Be willing and able to cooperate with the requirements of the study
  5. Be willing to apply sunscreen to the treatment areas before each exposure to the sun for the duration of the study (from the Screening Visit through the Day 180/Early Termination Visit).

Exclusion Criteria:

  1. Has a history of hypersensitivity or allergy to collagenase or any other excipients of CCH.
  2. During Screening has a CR-PCSS score of less than 2 or greater than 3 for the area to be treated (buttocks or thighs) and/or has a Hexsel CSS Subsection D "Grade of Laxity, Flaccidity, or Sagging Skin" score of less than 2 or greater than 3 (severe) for the areas to be treated (buttocks or thighs).
  3. Has a coagulation disorder, which requires anticoagulant or antiplatelet medication during the study (except for ≤150 mg aspirin daily), or has taken anticoagulant or antiplatelet medication(s) within 14 days before injection of study treatment (except for ≤150 mg aspirin daily).
  4. Is a prisoner, an individual with impaired decision making capacity, employees (temporary, part-time, full-time, etc) or a family member of the research staff conducting the study, or of the sponsor, or of the contract research organization, or of the Institutional Review Board (IRB)/Independent Ethics Committee (IEC), or in the judgment of the investigator the participant is disadvantaged and vulnerable to coercion due to lack of education, or due to poor economic circumstances.
  5. Has received any collagenase treatments at any time prior to treatment in this study and/or has received EN3835 or CCH in a previous investigational study for cellulite.
  6. Is pregnant and/or is breast-feeding or plans to become pregnant and/or to breast-feed during the course of the study.
  7. Has a history of scarring due to keloids or abnormal wound healing.
  8. Has local (in areas to be treated) conditions (thrombosis, vascular disorder, active infection/inflammation, active cutaneous alteration, tattoo/mole) that restricts study participation
  9. Has history of drug or alcohol abuse within the 5 years prior to the Screening Visit.
  10. Has evidence of clinically significant abnormalities, as judged by the investigator, in any of the following: physical examination findings, electrocardiogram (ECG), clinical laboratory values, or vital signs.

    The sponsor's medical monitor will be required to review the results for confirmation of eligibility in the case of any of the following: abnormalities in electrocardiograms indicating corrected QT interval (QTc) prolongation of 470 milliseconds or greater; and clinical laboratory values of liver enzymes

  11. Has used or intends to use any of the local application/therapies/injections/procedures that restricts study participation.
  12. Has any other condition(s) that, in the investigator's opinion, might indicate the participant to be unsuitable for the study.
  13. For the subset of participants participating in the collection of ultrasound data, the following exclusions will apply: participants will be excluded who have: a history of a spinal laminectomy, a previous history or presence of vascular abnormalities (for example, deep vein thrombosis, thrombophlebitis), a healing fracture, an impaired sensation within, or near, the planned treatment area, or any implants within, or near, the planned treatment area.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04580303


Locations
Layout table for location information
United States, Florida
Endo Clinical Trial Site #3
Coral Gables, Florida, United States, 33146
United States, Louisiana
Endo Clinical Trial Site #2
Metairie, Louisiana, United States, 70006
United States, New York
Endo Clinical Trial Site #1
New York, New York, United States, 10021
Sponsors and Collaborators
Endo Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: David Hernandez Endo Pharmaceuticals
  Study Documents (Full-Text)

Documents provided by Endo Pharmaceuticals:
Study Protocol  [PDF] December 3, 2020
Statistical Analysis Plan  [PDF] June 24, 2021

Layout table for additonal information
Responsible Party: Endo Pharmaceuticals
ClinicalTrials.gov Identifier: NCT04580303    
Other Study ID Numbers: EN3835-224
First Posted: October 8, 2020    Key Record Dates
Results First Posted: September 28, 2022
Last Update Posted: September 28, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cellulite
Skin Manifestations